Company news
Biogen Inc. news in 2021
Biogen Inc.'s news releases, calls and decks from 2021, newest first.
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease
December 19, 2021
Update on Regulatory Submission for Aducanumab in the European Union
December 16, 2021
Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
December 13, 2021
Update on Regulatory Review of Aducanumab in the European Union
November 16, 2021
The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis
November 15, 2021
Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
November 14, 2021
Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
November 2, 2021
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
October 16, 2021
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
September 20, 2021
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
September 19, 2021
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
September 15, 2021
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
September 14, 2021
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
August 1, 2021
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
July 28, 2021
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
July 25, 2021
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
July 11, 2021
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
July 7, 2021
Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
June 22, 2021
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
June 16, 2021
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
June 15, 2021
Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
June 13, 2021
Biogen Announces Investor Day on September 21, 2021
June 9, 2021
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
June 6, 2021
Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)
May 31, 2021
Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
May 20, 2021
Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland
May 19, 2021
Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
May 13, 2021
Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
May 12, 2021
Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
May 11, 2021
Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
May 9, 2021
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
April 27, 2021